指南与共识姑息放疗与转移瘤放疗物理与技术

骨转移姑息放疗中单次照射与立体定向体部放疗的推荐实践调查

Recommendations for Single-Fraction Radiation Therapy and Stereotactic Body Radiation Therapy in Palliative Treatment of Bone Metastases: A Statewide Practice Patterns Survey.
指南 / 共识 · Pract Radiat Oncol · 2019-07-19

结果显示单次照射总体推荐率仅16.1%,立体定向体部放疗推荐率16.4%;学术任职和高姑息病例量是单次照射的预测因素,学术任职、近期完成住院医师培训、脊柱部位和既往放疗是SBRT的预测因素。单次照射推荐率较2009年调查的9.4%有所提高。

要点

  • 单次照射推荐率16.1%,仍不常见但高于2009年的9.4%。
  • SBRT推荐率16.4%,脊柱部位和既往放疗是强预测因素。
  • 学术任职与高姑息病例量均与单次照射推荐相关。

核心结论

  • 单次照射放疗仍不常被推荐,但可能比10年前推荐更多,尽管SBRT使用增加。
  • 医生决策中影响单次照射推荐的多项关键驱动因素尚未被先前一级证据涉及。

研究设计与样本

  • 密歇根放射肿瘤学质量联盟成员调查,2017年4月至5月进行。
  • 医生对31个变量在剂量分割选择中的重要性评分,并覆盖7个患者场景。

主要发现

  • 选择剂量分割方案时评分最高的因素为体力状态、预后、脊髓压迫和既往放疗。
  • 7个场景中共推荐23种剂量分割方案。
  • 单次照射总体推荐率为16.1%。
  • SBRT总体推荐率为16.4%。
  • 单次照射推荐率高于2009年调查报告的9.4%(P = .0004)。

关键数值与推荐

  • 多变量分析中,单次照射使用相关因素:学术任职(OR 2.04;95% CI,1.02-4.08;P = .044)和高姑息病例量(OR 2.59;95% CI,1.45-4.63;P = .001)。
  • 多变量分析中,SBRT使用显著预测因素:学术任职(OR 2.99;95% CI,1.39-6.44;P = .005)、更近完成住院医师培训(OR 4.37;95% CI,1.26-15.17;P = .02)、脊柱部位(OR 12.54;95% CI,3.96-39.68;P < .001)和既往放疗(OR 26.67;95% CI,7.86-90.57;P < .001)。

临床怎么用

  • 调查提示单次照射在骨转移姑息治疗中推荐不足,尤其非学术机构或低姑息病例量医生。
  • 脊柱部位和既往放疗患者更倾向推荐SBRT。

局限性

  • 调查时间为2017年,结果可能不反映当前实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Single-fraction (SF) radiation therapy is effective and convenient for patients with painful noncomplex bone metastases. Prior survey results reported a low recommendation of SF radiation therapy in the US. We sought to assess contemporary treatment recommendations for the management of bone metastases among diverse physicians participating in a statewide quality consortium. METHODS AND MATERIALS: Members of the Michigan Radiation Oncology Quality Consortium were surveyed between April and May 2017. Physicians rated the importance of 31 variables on their choice of dose fractionation. The survey also covered 7 patient scenarios. RESULTS: Fifty-six physicians responded who were practicing at 18 of 20 centers surveyed. Respondents recommended 23 dose-fractionation schedules across the 7 scenarios. Highest-rated factors considered when choosing a dose fractionation regimen were performance status, prognosis, spinal cord compression, and prior radiation therapy. Recommendations for SF overall were uncommon (16.1%). On multivariable analysis, factors associated with SF use included academic employment (odds ratio [OR] 2.04; 95% CI, 1.02-4.08; P = .044) and higher palliative case volume (OR 2.59; 95% CI, 1.45-4.63; P = .001). Stereotactic body radiation therapy (SBRT) was recommended in 16.4% of scenarios overall, and on multivariable analysis, significant predictors for SBRT use were academic employment (OR 2.99; 95% CI, 1.39-6.44; P = .005), more recent residency completion (OR 4.37; 95% CI, 1.26-15.17; P = .02), spine location (OR 12.54; 95% CI, 3.96-39.68; P < .001), and prior radiation therapy (OR 26.67; 95% CI, 7.86-90.57; P < .001). SF rates were higher than in a survey reported in 2009 (16.1% vs 9.4%, P = .0004). CONCLUSIONS: SF radiation therapy remains uncommonly recommended, although it may be recommended more now than it was 10 years ago despite the increased utilization of SBRT. We identify multiple key drivers in physician decision making affecting SF recommendations that have not been addressed by prior level one evidence. Further research with evidence-based recommendations to clarify the role of SF and SBRT in management of patients with bony metastases are needed.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Gharzai LA, Beeler WH, Hayman JA, et al. Recommendations for Single-Fraction Radiation Therapy and Stereotactic Body Radiation Therapy in Palliative Treatment of Bone Metastases: A Statewide Practice Patterns Survey. Pract Radiat Oncol. 2019. PMID: 31326530. doi:10.1016/j.prro.2019.07.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。